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Abstract
Background: Hepatitis C virus is a highly immunogenic pathogen often inducing autoimmune
activation changes and this can often be further exacerbated by Interferon therapy. As HCV is
lymphocytotropic, it can modulate T cell and B cell antibody responses, affecting many endocrine
organs, most commonly the thyroid.
Case presentation: We hereby describe a case of fluctuating and wavering thyrotropin
autoantibodies of both stimulating and blocking nature in the setting of Graves's ophthalmopathy,
hepatitis C infection and interferon-α, causing hypo- and subsequently hyper-thyroidism. The
autoantibody profile was clearly modified during interferon therapy and settled into a new
equilibrium at the completion of treatment.
Conclusion: The case highlights the possible existence of a dual thyroid autoantibody population
associated with hepatitis C, and its modulation by interferon therapy, which further compounds
the difficulties in the assessment thyroid disease in this setting.
Background
Hepatitis C virus is a highly immunogenic pathogen often
inducing autoimmune activation changes and this can
often be further exacerbated by interferon therapy. As
HCV is lymphocytotropic, it can modulate T cell and B cell
antibody responses, affecting many endocrine organs,
most commonly the thyroid. As a result of this modulat-
ing effect, the thyroid autoantibody profile can be severely
affected, especially in the setting of Graves' disease super-
imposed with hepatitis C infection and interferon-based
treatment. The following case report illustrates this phe-
nomenon with fluctuating thyrotropin autoantibodies of
both stimulating and blocking nature during interferon
therapy. It is the existence of these changing antibodies
that compounds the difficulties of assessing thyroid dis-
ease in this setting.
Case Presentation
A 44 year-old Caucasian man with chronic hepatitis C
infection and known, long-standing primary hypothy-
roidism presented with recent onset Graves' ophthalmop-
athy (GO). There was no other medical problem and the
patient had otherwise been well. His hypothyroidism was
diagnosed 10 years prior, approximately at the same time
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as his hepatitis C. At that time, the thyrotropin (TSH) was
found to be 34 IU/L, free tetra-iodothyronine (fT4) 10.2
and free tri-iodothyronine (fT3) 3.2 pmol/L. He was
started on thyroxine therapy with subsequent satisfactory
control. No information on autoantibodies or imaging
was available from this presentation.
Clinical examination showed a tattooed man in euthy-
roidism. His ophthalmopathy was graded as moderate-to-
severe including >3 mm lid retraction and marked conges-
tion with a clinical activity score (CAS) of 5/7 [1]. Visual
acuities were 6/6 bilaterally. No goitre, dermatopathy or
acanthosis nigricans was detected. His liver span was nor-
mal at 11 cm and there was no evidence of chronic liver
disease, ascites or portal hypertension. His thyroid ultra-
sound scan showed 2 small nodules but was otherwise
normal in volume. His thyroid pertechnetate uptake scan
was reduced at 1% (reference range (RR), 3-8%) whilst on
150 μg of thyroxine daily, at which time his TSH was 1.98
(RR, 0.4-4.0 mU/L) and fT4 21.5 (RR, 10.2-24.5 pmol/L).
His antithyroperoxidase and antithyroglobulin antibod-
ies were undetectable. The thyrotropin receptor antibody
(TRAb) was 4.0 IU/L (reference interval, < 1.0 IU/L).
Other routine laboratory tests were normal including
aspartate and alanine aminotransferase activity. His base-
line viral load was 6.08 log IU/mL. His ocular magnetic
resonance imaging (MRI) supported the diagnosis of GO
(Figure 1).
Due to the diametrically opposite clinical findings of
hypothyroidism and GO, further bioassays were per-
formed to assess antibodies affecting the function of the
TSH receptors. The thyrotropin stimulating antibody
(TSAb) was 192 (RR, <180%) and thyrotropin blocking
antibody (TBAb) 124 (RR, <40%), suggesting that the
mechanism for his hypothyroidism was immune medi-
ated with TSH blocking activity.
Progress
Due to the presence of hypothyroidism and the potential
additional effect of interferon on thyroid tissue, hepatitis
C treatment was carefully started. Because of his hepatitis
C genotype 2, liver biopsy was deemed unnecessary and
thus was not performed [2]. Treatment then included
combination interferon-α and ribavirin for 24 weeks. The
ophthalmopathy did not worsen and was managed con-
servatively with liquid film eye drops and protective
glasses. The CAS remained unchanged. Both his eye and
thyroid status was monitored and closely reviewed every
month. On the 8th week, his TSH declined, necessitating a
reduction in thyroxine dosage. At 16 week, he was found
to be biochemically thyrotoxic with suppressed TSH, fT4
of 28.9 and fT3 of 6.9 pmol/L at which time his thyroxine
was ceased. The TSH stimulating activity increased whilst
blocking activity declined. His TSAb rose further whilst
blocking activity declined. The evolution of the antibody
profile is summarised in Figure 2. The thyroid uptake scan
evolved to show a diffuse and increased in uptake at 12%.
The potential and aggravating effects of elevated TSAb
titres on the ophthalmopathy were duly considered but
observation was continued (see below).
As the patient was asymptomatic, his thyroid condition
was also observed closely. His serial fT4 and fT3 levels
remained high but unaltered throughout the course of
therapy (Figure 2). Four weeks after the completion of
therapy, his TSH was 0.05 mIU/L, fT4 21.5 and fT3 4.9
pmol/L. At 12 weeks, his level had become progressively
hypothyroid with TSH of 5.9 mIU/L and fT4 17.9 pmol/L.
At the subsequent 6, 12, 24 and 36 months follow-ups,
his TSH levels ranged between 5.3 and 6.4 mIU/L. His
viral load was undetectable at the 6-month follow-up con-
sistent with sustained virologic response.
Methods
TRAb assay was measured with the TRAK LUMI test
(B.R.A.H.M.S.AG, Hennigsdorf/Berlin, Germany). A TRAb
level of <1.0 IU/L is considered negative and > 1.5 as con-
clusively positive. TSAb and TBAb bioassays were meas-
Magnetic Resonance Imaging of the orbits, showing conges- tion of the retro-orbital space and enlargement of the  extraocular muscles (arrows), consistent with the diagnosis of  Graves' Ophthalmopathy Figure 1
Magnetic Resonance Imaging of the orbits, showing 
congestion of the retro-orbital space and enlarge-
ment of the extraocular muscles (arrows), consistent 
with the diagnosis of Graves' Ophthalmopathy.Thyroid Research 2009, 2:12 http://www.thyroidresearchjournal.com/content/2/1/12
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ured as previously described [3,4]. Generally, the
detection was carried out in low salt conditioning using
JPO9 Chinese hampster ovary cells transfected with the
human TSH-R. Cyclic AMP was measured in a commercial
RIA (Amersham, Aylesbury, UK). Thyroid stimulation
index (SI) was calculated as: SI (percent) = 100 × (cAMP
patient/cAMP euthyroid control). For TBAb detection,
bovine TSH (1 mU/mL; Sigma, St. Louis, MO) was added
with either euthyroid control or test serum. The inhibition
index (InI) was calculated as: InI (percent) = 100 × [1 -
(counts per minute patient/counts per minute euthyroid
control)].
Third generation serum thyrotropin (TSH), serum free
tetra- and free tri-iodothyronine (fT4 and fT3) were deter-
mined by two-site sandwich immunoassay using an auto-
mated chemiluminescent system (Diagnostic Products
Corporation, Immulite 2000). The reference range (RR)
for TSH was 0.4-4.0 mU/L, fT4 10.0-26.0 and fT3 3.5-5.5
pmol/L. The coefficients of variations (CV) were 5.0% and
5.1% at TSH concentrations of 4.0 mU/L and 10.0 mU/L
respectively. For fT4, the CV was 6.5% at 10.0 pmol/L and
fT3 8.9% at 3.5 pmol/L.
Serum autoantibodies to thyroglobulin and thyroperoxi-
dase were measured by agglutination (Serodia-ATG and
Serodia-AMC, Fujirebio, Inc., Tokyo, Japan). Titres of less
than 1:400 were considered normal for both.
Discussion
Although the co-existence of dual thyroid TSAb and TBAb
has been well documented [5], its pattern in the presence
of hepatitis C and its modulation by interferon treatment
has rarely been reported previously [6]. The present case
highlights the population of thyroid autoantibodies
whose evolution is significantly influenced in the pres-
The immunomodulating effect of Interferon therapy on the TS and TB subsets of autoantibodies and its effects on thyroxine  dosage and nuclear uptake patterns Figure 2
The immunomodulating effect of Interferon therapy on the TS and TB subsets of autoantibodies and its 
effects on thyroxine dosage and nuclear uptake patterns. Note: the graphs are only approximate representations, not 
to exact scale.
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ence of hepatitis C and interferon. It was highly likely that
the initial diagnosis of hypothyroidism was the result of
TSH blocking activity resulting in the biochemical expres-
sion of hypothyroidism. In the absence of further infor-
mation at the time of diagnosis, it was hard to confirm
this hypothesis. However, in favour of this diagnosis was
the absent/negligible nuclear uptake in the thyroid scan,
the presence of a normal-size thyroid on ultrasound and
the absence of any thyroid auto-antibodies. Although
excessive thyroxine can affect thyroid uptake scan appear-
ance, in the presence of a normal (non-suppressed) TSH
level, it is very likely that the uptake scan reflects the activ-
ity of TBAbs.
The development of GO is a fascinating feature that must
closely involve the presence of TRAb. Although the patho-
genesis of GO remains undetermined, TSAb is one of the
major contributors in inducing the inflammatory process
in the orbital fat and ocular muscles resulting in swelling
and congestion of the orbit [7]. In addition, recent case
reports suggested an association between hepatitis C
infection and GO [8,9]. Hypothetically, prior to the devel-
opment of GO, there must have existed an equilibrium
between these two sub-classes of thyroid antibodies,
albeit unbalanced in favour of TBAb, just sufficient to
elicit the hypothyroidism but with enough stimulating
activity to participate in the development of GO. In the
presence of interferon as an immuno-modulator, the
equilibrium then shifted in favour of TSAb and hence the
progressive thyrotoxic biochemical profile with marked
nuclear uptake. It was conceivable but unlikely that this
shift was spontaneous and coincidental because his thy-
roid status was stable in the intervals following interferon
therapy. This would have been further bolstered if his thy-
roid parameters were available in the period preceding
hepatitis C treatment. These changes appeared permanent
as the hypothyroidism moderated compared to before
treatment. Despite the mildly elevated TSH level, no thy-
roxine was required 3 years after the completion of inter-
feron therapy. This is underlined by the newly
equilibrated antibody profile at the end of treatment, with
both TS- and TB-Ab subclass activities being normal.
These were not performed further in the convalescing
period. Interestingly, the relatively higher TS-Ab activity
did not further compound the ophthalmopathy.
The management of GO in this case was both challenging
and difficult, involving plentiful of discussion with the
patient and his spouse. As mentioned, the addition of
interferon may aggravate the GO which in turn may be
further exacerbated by the evolving TSAb, potentially pre-
cipitating an ophthalmic crisis and loss of vision [9]. On
the other hand, independent treatment with immunosup-
pressants such as glucocorticoid, calcineurin inhibiting
agents or methotrexate can potentially lead to fulminant
hepatic necrosis and failure. After much deliberation and
risk estimation, the GO was monitored closely with visual
acuities and color charts weekly, tapering to monthly as
the condition remained progressively stable. Although the
natural history of this condition is unknown in this set-
ting and to be safe, orbital irradiation and decompressive
surgery were also consulted and made readily available.
Fortunately, his ophthalmic condition did not deterio-
rate.
The underlying pathogenesis of this swinging antibody
profile is unknown. Although the prevalence of hypothy-
roidism in the setting of hepatitis C and interferon is not
uncommon, this rare type of hypothyroidism often goes
unsuspected unless there are other indicators such as oph-
thalmopathy. The antibodies switching to the TSH recep-
tors must be modulated, evolving from blocking to
predominantly stimulating. It is both a relief and fascina-
tion that GO failed to progress as TSAb has been suggested
to initiate and stimulate orbital adipogenesis [10]. Recent
studies were able to further investigate the inhibitory and
stimulatory nature of these antibodies. In fact mono-
clonal antibodies with both stimulating and block activi-
ties were recently developed. Plausibly the relevant B cells
are selected to alter the variable regions of the immu-
noglobulins to specifically affect the critical areas for TSH
receptors stimulation and blockade, particularly region
M22 and 5C9 of the TSH autoantibodies [11,12]. It must
be noted however that the switching between hyper- and
hypothyroid phases of Graves' disease can occur inde-
pendent of hepatitis C infection and interferon therapy
[13]
In HCV infection, there is also an increased secretion of
IFN-γ and chemokine ligand 10 (CXCL10) generally as
well as by thyrocytes [14]. The high CXCL10 level is
higher in patients who develop thyroid disease, especially
hypothyroidism in the setting of hepatitis C. It is possible
that the endo-, exo-genous interferon and CXCL 10 com-
bine to modify the immune response. The elevated
CXCL10 level has also been implicated in GO recently
[15]. These factors may add to the aforementioned mech-
anisms to result in the complex immuno-chemical cas-
cade representative of this case. This is purely speculative
however and this observed immune phenomenon
remains poorly understood. It adds to the spectrum of
thyroid diseases in the presence of hepatitis C and in par-
ticular its modulation by interferon therapy [16].
Conclusion
This case highlights another fascinating and complex
interaction between the thyroid and interferon therapy in
hepatitis C infection. Although highly unusual, hypothy-
roidism potentially due to TBAb should be thoroughly
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